3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
106
Neoplasm Metastasis
9
Ovarian Neoplasms
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Prostatic Neoplasms
2
Obesity
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Breast Carcinoma In Situ
2
Breast Cancer Metastatic
2
Arthralgia
2
Triple Negative Breast Neoplasms
1
Sexuality
1
Sexual Dysfunctions, Psychological
1
Recurrence
1
Primary Breast Cancer ER+ve
1
Premenopausal Breast Cancer
1
Patient Acceptance of Health Care
1
Pancreatic Neoplasms
1
Pain
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Beast Cancer
1
Locoregional Recurrence
1
Hyperglycemia
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hormone Receptor Positive Malignant Neoplasm of Breast
1
HR Positive HER2 Negative Advanced Breast Cancer
1
Interventions
pembrolizumab
1
exemestane
1
Tamoxifen
1
Surgical Procedures, Operative
1
Leuprolide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Premenopausal Breast Cancer
×
exemestane
×
Clear all
NCT02990845
2023-02-22
PEER
National Taiwan University Hospital
Phase 1/2
Terminated
16 enrolled